Recent Updates
Recently added Catalysts

Warm Autoimmune Hemolytic Anemia: two biotech companies racing to a treatment

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$3.8Buniverse median $1.20B
Allocated capital$2.4B$7.6B competing
Phase 3 or filed10 mid, 1 early
Pure plays0this indication only
Capital rank84/299crowding rank 82

Warm Autoimmune Hemolytic Anemia is a two-horse race: Zenas BioPharma (ZBIO, $2.1B) against CRISPR Therapeutics (CRSP, $5.5B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $2.4B of allocated capital sits on the pair.

CRSP carries 72% of the $7.6B competing here, so the pair is far from evenly matched.

$2.4B of allocated capital sits in Warm Autoimmune Hemolytic Anemia, ranking it 84th of 299 indications by the money committed to it.

Companies developing drugs for Warm Autoimmune Hemolytic Anemia 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ZBIOZenas BioPharmaObexelimabPhase 31$2.1BNo4 31 Dec 2026
CRSPCRISPR TherapeuticsCTX112Phase 11$5.5BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. CRSP holds 72% of the $7.6B competing in this indication.

Why Warm Autoimmune Hemolytic Anemia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Warm Autoimmune Hemolytic Anemia has 2 competitors and a median of $3.8B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Alopecia Areata3 companies · $2.2B · median $1.6BConcentrated betWrinkles1 company · $2.2B · median $11.0BUncontestedPrimary Biliary Cholangitis1 company · $2.2B · median $6.5BUncontestedPrimary Sclerosing Cholangitis1 company · $2.2B · median $6.5BUncontestedGraves' Disease2 companies · $2.0B · median $5.2BConcentrated betRosacea1 company · $1.8B · median $3.7BUncontestedFocal Segmental Glomerulosclerosis2 companies · $1.7B · median $3.3BConcentrated betANCA-associated Vasculitis2 companies · $1.7B · median $3.3BConcentrated bet

Warm Autoimmune Hemolytic Anemia pipeline questions

Which biotech companies are developing drugs for Warm Autoimmune Hemolytic Anemia?

Zenas BioPharma (ZBIO, Obexelimab, Phase 3); CRISPR Therapeutics (CRSP, CTX112, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Warm Autoimmune Hemolytic Anemia.

How advanced is the Warm Autoimmune Hemolytic Anemia pipeline?

Of the 2 clinical-stage programmes in Warm Autoimmune Hemolytic Anemia, 1 is in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Which company leads the Warm Autoimmune Hemolytic Anemia field?

CRSP is the largest developer in Warm Autoimmune Hemolytic Anemia, holding 72% of the $7.6B of market capitalisation competing in the indication. The median competitor is worth $3.8B.

When is the next Warm Autoimmune Hemolytic Anemia catalyst?

The next dated catalyst in Warm Autoimmune Hemolytic Anemia is ZBIO on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map